ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Crizotinib is highly effective in patients with ALK-positive NSCLC, similarly to the effects of imatinib in BCR-ABL-positive CML or of gefitinib in EGFR-mutated NSCLC.